Tirzepatide for managing overweight and obesity

Tirzepatide (Mounjaro, Eli Lilly) is indicated for 'weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of:

• ≥30 kg/m² (obesity) or

• ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)'.

The dosage schedule is available in the summary of product characteristics for tirzepatide.

The list prices of tirzepatide (excluding VAT; company communication) for a 4-week supply of pre-filled pen devices for subcutaneous injection are:

• £133.00 for 2.5 mg 

• £180.00 for 5 mg 

• £255.00 for 7.5 mg and 10 mg  

• £330.00 for 12.5 mg and 15 mg.

The company has a commercial arrangement. This makes tirzepatide available to the NHS at a cost-effective price determined by NICE. The details of this arrangement are commercial in confidence.